Novel midkine inhibitor iMDK inhibits tumor growth and angiogenesis in oral squamous cell carcinoma

Masanori Masui, Tatsuo Okui, Tsuyoshi Shimo, Kiyofumi Takabatake, Takuya Fukazawa, Kenichi Matsumoto, Naito Kurio, Soichiro Ibaragi, Yoshio Naomoto, Hitoshi Nagatsuka, Akira Sasaki

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Midkine is a heparin-binding growth factor highly expressed in various human malignant tumors. However, its role in the growth of oral squamous cell carcinoma is not well understood. In this study, we analyzed the antitumor effect of a novel midkine inhibitor (iMDK) against oral squamous cell carcinoma. Administration of iMDK induced a robust antitumor response and suppressed cluster of differentiation 31 (CD31) expression in oral squamous cell carcinoma HSC-2 cells and SAS cells xenograft models. iMDK inhibited the proliferation of these cells dose-dependently, as well as the expression of midkine and phospho-extracellular signal-regulated kinase in HSC-2 and SAS cells. Moreover, iMDK significantly inhibited vascular endothelial growth factor and induced tube growth of human umbilical vein endothelial cells in a dose-dependent fashion. These findings suggest that midkine is critically involved in oral squamous cell carcinoma and iMDK can be effectively used for the treatment of oral squamous cell carcinoma.

Original languageEnglish
Pages (from-to)2775-2781
Number of pages7
JournalAnticancer research
Issue number6
Publication statusPublished - Jun 2016


  • Angiogenesis
  • IMDK
  • Midkine
  • Oral squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel midkine inhibitor iMDK inhibits tumor growth and angiogenesis in oral squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this